Vericel Reduces MACI Guide on Patient Flow Downturn

Vericel reported 3Q22 orthopedic sales of $31 million, +29.8% compared to the third quarter of 2021.

The company's MACI product defied normal seasonality. It grew 8% sequentially in the third quarter despite the usually flat summer season. However, Vericel said the overall cartilage repair market declined 10% this year due to ongoing...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us